Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

InMed Pharmaceuticals (INM) Payables: 2022-2025

Historic Payables for InMed Pharmaceuticals (INM) over the last 4 years, with Jun 2025 value amounting to $1.4 million.

  • InMed Pharmaceuticals' Payables rose 11.72% to $1.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.3 million, marking a year-over-year increase of 3.48%. This contributed to the annual value of $1.4 million for FY2025, which is 15.10% down from last year.
  • According to the latest figures from FY2025, InMed Pharmaceuticals' Payables is $1.4 million, which was down 15.10% from $1.7 million recorded in FY2024.
  • In the past 5 years, InMed Pharmaceuticals' Payables registered a high of $2.4 million during FY2022, and its lowest value of $1.4 million during FY2025.
  • Over the past 3 years, InMed Pharmaceuticals' median Payables value was $1.6 million (recorded in 2023), while the average stood at $1.6 million.
  • As far as peak fluctuations go, InMed Pharmaceuticals' Payables tumbled by 33.39% in 2023, and later rose by 2.81% in 2024.
  • Over the past 4 years, InMed Pharmaceuticals' Payables (Yearly) stood at $2.4 million in 2022, then plummeted by 33.39% to $1.6 million in 2023, then increased by 2.81% to $1.7 million in 2024, then decreased by 15.10% to $1.4 million in 2025.